Literature DB >> 19763887

Receptor-targeted anticancer therapy.

Ben K Seon1, Yuro Haruta, Fumihiko Matsuno, Akinao Haba, Norihiko Takahashi, Xinwei She, Naoko Harada, Shima Uneda, Masanori Tsujie, Tomoko Tsujie, Hirofumi Toi, Hilda Tsai.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 19763887      PMCID： PMC4353395          DOI： 10.1007/s12026-009-8131-8

Source DB:  PubMed          Journal:  Immunol Res        ISSN： 0257-277X            Impact factor:   2.829


× No keyword cloud information.
  10 in total

1.  Induction of lasting complete regression of preformed distinct solid tumors by targeting the tumor vasculature using two new anti-endoglin monoclonal antibodies.

Authors:  F Matsuno; Y Haruta; M Kondo; H Tsai; M Barcos; B K Seon
Journal:  Clin Cancer Res       Date:  1999-02       Impact factor: 12.531

2.  Antibody-drug conjugates targeted to CD79 for the treatment of non-Hodgkin lymphoma.

Authors:  Andrew G Polson; Shang-Fan Yu; Kristi Elkins; Bing Zheng; Suzanna Clark; Gladys S Ingle; Dionysos S Slaga; Lynne Giere; Changchun Du; Christine Tan; Jo-Anne Hongo; Alvin Gogineni; Mary J Cole; Richard Vandlen; Jean-Philippe Stephan; Judy Young; Wesley Chang; Suzie J Scales; Sarajane Ross; Dan Eaton; Allen Ebens
Journal:  Blood       Date:  2007-03-20       Impact factor: 22.113

3.  Association of serum endoglin with metastasis in patients with colorectal, breast, and other solid tumors, and suppressive effect of chemotherapy on the serum endoglin.

Authors:  N Takahashi; R Kawanishi-Tabata; A Haba; M Tabata; Y Haruta; H Tsai; B K Seon
Journal:  Clin Cancer Res       Date:  2001-03       Impact factor: 12.531

4.  Antiangiogenic chimeric anti-endoglin (CD105) antibody: pharmacokinetics and immunogenicity in nonhuman primates and effects of doxorubicin.

Authors:  Ken Shiozaki; Naoko Harada; William R Greco; Akinao Haba; Shima Uneda; Hilda Tsai; Ben K Seon
Journal:  Cancer Immunol Immunother       Date:  2005-04-23       Impact factor: 6.968

5.  Identification of a human endothelial cell antigen with monoclonal antibody 44G4 produced against a pre-B leukemic cell line.

Authors:  A Gougos; M Letarte
Journal:  J Immunol       Date:  1988-09-15       Impact factor: 5.422

6.  Distinct human leukemia-associated cell surface glycoprotein GP160 defined by monoclonal antibody SN6.

Authors:  Y Haruta; B K Seon
Journal:  Proc Natl Acad Sci U S A       Date:  1986-10       Impact factor: 11.205

7.  Three new monoclonal antibodies that define a unique antigen associated with prolymphocytic leukemia/non-Hodgkin's lymphoma and are effectively internalized after binding to the cell surface antigen.

Authors:  M Okazaki; Y Luo; T Han; M Yoshida; B K Seon
Journal:  Blood       Date:  1993-01-01       Impact factor: 22.113

8.  Anti-tumor activity of an anti-endoglin monoclonal antibody is enhanced in immunocompetent mice.

Authors:  Masanori Tsujie; Tomoko Tsujie; Hirofumi Toi; Shima Uneda; Ken Shiozaki; Hilda Tsai; Ben K Seon
Journal:  Int J Cancer       Date:  2008-05-15       Impact factor: 7.396

9.  Isolation and chemical characterization of the human B29 and mb-1 proteins of the B cell antigen receptor complex.

Authors:  S Vasile; J E Coligan; M Yoshida; B K Seon
Journal:  Mol Immunol       Date:  1994-04       Impact factor: 4.407

10.  Long-lasting complete inhibition of human solid tumors in SCID mice by targeting endothelial cells of tumor vasculature with antihuman endoglin immunotoxin.

Authors:  B K Seon; F Matsuno; Y Haruta; M Kondo; M Barcos
Journal:  Clin Cancer Res       Date:  1997-07       Impact factor: 12.531
  10 in total
  1 in total

1.  Effects of the combination of TRC105 and bevacizumab on endothelial cell biology.

Authors:  Yingmiao Liu; Hongyu Tian; Gerard C Blobe; Charles P Theuer; Herbert I Hurwitz; Andrew B Nixon
Journal:  Invest New Drugs       Date:  2014-07-05       Impact factor: 3.850
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.